10-QPeriod: Q1 FY2004

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2004

Filed May 6, 2004For Securities:BIIB

Summary

Biogen Idec Inc. reported a net loss of $41.2 million, or $0.12 per share, for the first quarter of 2004, a significant shift from the $41.2 million net income, or $0.24 per diluted share, reported in the same period of 2003. This loss is primarily attributed to the impact of the November 2003 merger with Biogen, Inc., which resulted in substantial amortization of acquired intangible assets and the recognition of product cost of sales on inventory acquired at fair value. Total revenues significantly increased to $541.7 million from $117.2 million year-over-year, driven by the inclusion of former Biogen, Inc. products like AVONEX and AMEVIVE, alongside strong performance from the unconsolidated joint business, primarily RITUXAN. However, operating expenses also saw a dramatic rise, largely due to the merger-related costs, including increased research and development and selling, general, and administrative expenses. The company ended the quarter with a strong liquidity position, with cash and cash equivalents of $302.8 million.

Key Highlights

  • 1Net loss of $41.2 million ($0.12/share) in Q1 2004, a reversal from a $41.2 million net income ($0.24/share) in Q1 2003.
  • 2Total revenues surged to $541.7 million in Q1 2004, up from $117.2 million in Q1 2003, primarily due to the inclusion of AVONEX and AMEVIVE sales post-merger.
  • 3Operating expenses increased significantly to $625.6 million from $54.1 million, largely due to merger-related amortization and operating costs.
  • 4Cost of sales increased substantially to $254.8 million, impacted by purchase accounting adjustments for inventory acquired in the merger.
  • 5Research and development expenses rose to $159.2 million from $31.9 million, reflecting increased investment post-merger.
  • 6Selling, general, and administrative expenses increased to $130.8 million from $21.3 million, primarily due to merger integration costs.
  • 7The company maintained a strong cash position with $302.8 million in cash and cash equivalents as of March 31, 2004.

Frequently Asked Questions

The primary reason for the shift from net income to a net loss is the impact of the merger with Biogen, Inc. completed in November 2003. This resulted in significant amortization of acquired intangible assets and higher cost of sales due to the valuation of acquired inventory at fair market value, which more than offset the substantial increase in revenues.

The merger significantly diversified and expanded revenue streams. Total revenues increased dramatically from $117.2 million in Q1 2003 to $541.7 million in Q1 2004. This growth is largely due to the inclusion of sales from AVONEX and AMEVIVE (acquired in the merger) alongside the established RITUXAN revenues generated through the unconsolidated joint business arrangement.

Operating expenses, including R&D and SG&A, have increased substantially due to the merger. Research and development expenses rose from $31.9 million to $159.2 million, and SG&A expenses increased from $21.3 million to $130.8 million. Management anticipates these expenses will continue to be higher in 2004 compared to 2003 due to ongoing integration, development, and commercialization efforts for existing and new products, including ANTEGREN.

Despite the net loss, the company maintained a strong liquidity position. Cash and cash equivalents stood at $302.8 million as of March 31, 2004. Net cash from operating activities was positive at $198 million, boosted by non-cash charges like depreciation and amortization, and the impact of fair value adjustments on inventory. Investing activities saw a significant outflow of $315.9 million, primarily related to marketable securities and capital expenditures.